Rigel Pharmaceuticals Inc. Q2 Loss beats estimates

Rigel Pharmaceuticals Inc. (RIGL) announced Loss for second quarter that beat the Street estimates.

The company's bottom line totaled -$13.49 million, or -$0.08 per share. This compares with -$13.82 million, or -$0.08 per share, in last year's second quarter.

Analysts on average had expected the company to earn -$0.12 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 13.5% to $29.82 million from $26.27 million last year.

Rigel Pharmaceuticals Inc. earnings at a glance (GAAP) :

-Earnings (Q2): -$13.49 Mln. vs. -$13.82 Mln. last year.
-EPS (Q2): -$0.08 vs. -$0.08 last year.
-Analyst Estimates: -$0.12
-Revenue (Q2): $29.82 Mln vs. $26.27 Mln last year.

For comments and feedback contact: editorial@rttnews.com

Follow RTT